A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
NCT ID: NCT00150709
Last Updated: 2024-02-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
223 participants
INTERVENTIONAL
1998-01-26
2006-01-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy
NCT00361010
Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures
NCT00152516
Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution
NCT01210690
Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy
NCT00150748
Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).
NCT00291655
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
N159 PBO/LEV
Subjects had previously participated in study N159 in which they had received Placebo (PBO).
Levetiracetam
* Pharmaceutical form: Oral tablets and oral solution
* Route of administration: Oral use
N159 LEV/LEV
Subjects had previously participated in study N159 in which they had received Levetiracetam (LEV).
Levetiracetam
* Pharmaceutical form: Oral tablets and oral solution
* Route of administration: Oral use
N01010+N151 LEV/LEV
Subjects had previously participated in study N01010 or study N151 in which they had received Levetiracetam (LEV).
Levetiracetam
* Pharmaceutical form: Oral tablets and oral solution
* Route of administration: Oral use
N01052 LEV/LEV
Subjects had previously participated in study N01052 in which they had received Levetiracetam (LEV).
Levetiracetam
* Pharmaceutical form: Oral tablets and oral solution
* Route of administration: Oral use
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levetiracetam
* Pharmaceutical form: Oral tablets and oral solution
* Route of administration: Oral use
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be a patient for whom the treatment of Levetiracetam (Keppra®) would be of potential benefit such that the patient/parent(s)/legal guardian and the Investigator agree to continue treatment.
Exclusion Criteria
* Not have seizures too close together to accurately count (i.e., the patient's seizures must be countable).
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
001 844 599 2273 (UCB)
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N157
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.